Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188208 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
A Phase 1 study of Advanced Solid Tumors and Advanced Hematologic Tumors, sponsored by Vividion Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT06188208: Active Phase 1 study of Advanced Solid Tumors and Advanced Hematologic Tumors, sponsored by Vividion Therapeutics.
NCT06188208 is a Phase 1 study of Advanced Solid Tumors and Advanced Hematologic Tumors that is active but no longer recruiting, run by Vividion Therapeutics. The registered enrollment target is 125 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06188208, a Phase 1 study of Advanced Solid Tumors and Advanced Hematologic Tumors, is active but no longer recruiting, sponsored by Vividion Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Primary Outcome
Incidence and severity of DLTs will be assessed per DLT criteria set forth in the protocol based on adverse events (AEs) evaluated per National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG VVD-130850
Study Locations (20)
Other
- Cancer Research South Australia - Adelaide
- ICON Cancer Research - South Brisbane
- START Barcelona Hospital HM Nou Delfos - Barcelona
- Vall d'Hebron - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
- NEXT Madrid - Madrid
- START Madrid CIOCC - Madrid
- Start Madrid-FJD, Hospital Fundacion Jimenez Diaz - Madrid
Texas
- NEXT Austin - Austin
- MDACC - Houston
- NEXT Dallas - Irving
- NEXT San Antonio - San Antonio
New South Wales
- Blacktown Hospital - Blacktown
- Orange Health Service - Orange
California
- California Research Institute - Los Angeles
Florida
- Florida Cancer Specialists - Sarasota
Tennessee
- Sarah Cannon Research Institute - Nashville
Utah
- University of Utah Huntsman Cancer Institute - Salt Lake City
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What the registry record for NCT06188208 still lists
NCT06188208 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% lower).
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06188208 names 20 study sites across 9 states, led by Other, Texas, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06188208 about?
NCT06188208 is a clinical study titled "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors". A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
What is the current status of trial NCT06188208?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2024-01-05. Estimated completion is 2027-01.
What conditions does trial NCT06188208 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Advanced Hematologic Tumors.
What interventions are being tested in trial NCT06188208?
The interventions under investigation include: Pembrolizumab (DRUG), VVD-130850 (DRUG).
Who is sponsoring clinical trial NCT06188208?
This trial is sponsored by Vividion Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188208 being conducted?
This trial has 20 study locations across California, Florida, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06188208's enrollment target sits among peer trials
125 68th of 144 higher than 77 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI